Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of PMN310 Infusions in Healthy Volunteers

NCT06105528 is registered in ClinicalTrials.gov with ProMis Neurosciences, Inc as lead sponsor.

NCT NCT06105528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06105528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of PMN310 Infusions in Healthy Volunteers
Lead sponsor
ProMis Neurosciences, Inc
Phase
Phase 1
Overall status
Completed
Start date
November 18, 2023
Completion date
July 31, 2024
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants